NCT05344157View on ClinicalTrials.gov

A First-in-Human Study of XSTEM-OA in Patients With Knee Osteoarthritis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

June 18, 2025

Study Completion Date

June 18, 2025

Conditions
Osteoarthritis, Knee
Interventions
BIOLOGICAL

XSTEM-OA

XSTEM-OA is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of osteoarthritis.

Trial Locations (2)

2292

Genesis Research Services, Broadmeadow

3124

Emeritus Research, Camberwell

All Listed Sponsors
collaborator

Xintela AB

INDUSTRY

lead

Xindu Pty Ltd

INDUSTRY